Gregory A Eschenauer

Dr. Gregory A Eschenauer

College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-1065, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
Gregory A EschenauerGregory A Eschenauer
Gregory A Eschenauer
DDDaryl D DePestel
Daryl D DePestel
PCPeggy L Carver
Peggy L Carver
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing

1 November 2019 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
LPLindsay A. Petty
Lindsay A. Petty
VVValerie M. Vaughn
Valerie M. Vaughn
SFScott A. Flanders
Scott A. Flanders
AMAnurag N. Malani
Anurag N. Malani
ACAnna Conlon
Anna Conlon
TGTejal N. Gandhi
Tejal N. Gandhi
Urinary tract infections (UTIs) are the second most common infection among hospitalized patients.1 Accurate diagnosis requires a combination of relevant signs and symptoms, generally supported by a positive urine culture (UC). Bacterial growth in a UC without accompanying symptoms is known as asymptomatic bacteriuria (ASB).2,3 Asymptomatic bacteriuria is commonly misdiagnosed as UTI.4 However, unlike UTI, treatment of ASB with antibiotics does not improve outcomes in outpatient and long-term care settings except in pregnancy or patients undergoing invasive urologic procedures.2,3,5 Despite national guidelines recommending against antibiotic therapy for ASB, high treatment rates persist.6-9

20 December 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSRyan K. Shields
Ryan K. Shields
CCCornelius Clancy
Cornelius Clancy
LGLouise M. Gillis
Louise M. Gillis
EKEun J. Kwak
Eun J. Kwak
FSFernanda P. Silveira
Fernanda P. Silveira
MNM. Hong Nguyen
M. Hong Nguyen
Extensively drug-resistant Acinetobacter baumannii (XDR-Ab) has emerged as a major nosocomial pathogen, but optimal treatment regimens are unknown. Although solid organ transplant (SOT) recipients are particularly susceptible to XDR-Ab infections, studies in this population are limited. Our objectives were to determine the epidemiology, clinical characteristics and outcomes of XDR-Ab infections among SOT patients. A retrospective study of SOT recipients at our center who were colonized or infected with XDR-Ab between November 2006 and December 2011 was conducted. Among infected patients, the primary outcome was survival at 28 days. Secondary outcomes included survival at 90 days and clinical success at 28 days, and XDR-Ab infection recurrence. XDR-Ab was isolated from 69 SOT patients, of whom 41% (28) and 59% (41) were colonized and infected, respectively. Infections were significantly more common among cardiothoracic than abdominal transplant recipients (p = 0.0004). Ninety-eight percent (40/41) of patients had respiratory tract infections, most commonly ventilator-associated pneumonia (VAP; 88% [36/41]). Survival rates at 28 and 90 days were 54% (22/41) and 46% (19/41), respectively. Treatment with a colistin-carbapenem regimen was an independent predictor of 28-day survival (p = 0.01; odds ratio = 7.88 [95% CI: 1.60–38.76]). Clinical success at 28 days was achieved in 49% (18/37) of patients who received antimicrobial therapy, but 44% (8/18) of successes were associated with infection recurrence within 3 months. Colistin resistance emerged in 18% (2/11) and 100% (3/3) of patients treated with colistin-carbapenem and colistin-tigecycline, respectively (p = 0.03). XDR-Ab causes VAP and other respiratory infections following SOT that are associated with significant recurrence and mortality rates. Cardiothoracic transplant recipients are at greatest risk. Results from this retrospective study suggest that colistin-carbapenem combinations may result in improved clinical responses and survival compared to other regimens and may also limit the emergence of colistin resistance.

1 June 2010 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
MNMay Nguyen
May Nguyen
Gregory A EschenauerGregory A Eschenauer
Gregory A Eschenauer
MBMonique Bryan
Monique Bryan
KOKelly O'NEil
Kelly O'NEil
EFE. Yoko Furuya
E. Yoko Furuya
CKChristine J. Kubin
Christine J. Kubin

30 October 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
Gregory A EschenauerGregory A Eschenauer
Gregory A Eschenauer
EKE. J. Kwak
E. J. Kwak
AHA. Humar
A. Humar
BPB. A. Potoski
B. A. Potoski
LCL. G. Clarke
L. G. Clarke
MNM. H. Nguyen
M. H. Nguyen
Guidelines recommend targeted antifungal prophylaxis for liver transplant (LT) recipients based on tiers of risk, rather than universal prophylaxis. The feasibility and efficacy of tiered, targeted prophylaxis is not well established. We performed a retrospective study of LT recipients who received targeted prophylaxis (n = 145; voriconazole [VORI; 54%], fluconazole [8%], no antifungal [38%]) versus universal VORI prophylaxis (n = 237). Median durations of targeted and universal prophylaxis were 11 and 6 days, respectively (p < 0.0001). The incidence of invasive fungal infections (IFIs) in targeted and universal groups was 6.9% and 4.2% (p = 0.34). Overall, intra‐abdominal candidiasis (73%) was the most common IFI. Posttransplant bile leaks (p = 0.001) and living donor transplants (p = 0.04) were independent risk factors for IFI. IFIs occurred in 6% of high‐risk transplants who received prophylaxis and 4% of low‐risk transplants who did not receive prophylaxis (p = 1.0). Mortality rates (100 days) were 10% (targeted) and 7% (universal) (p = 0.26); attributable mortality due to IFI was 10%. Compliance with prophylaxis recommendations was 97%. Prophylaxis was discontinued for toxicity in 2% of patients. Targeted antifungal prophylaxis in LT recipients was feasible and safe, effectively prevented IFIs and reduced the number of patients exposed to antifungals. Bile leaks and living donor transplants should be considered high‐risk indications for prophylaxis.

1 August 2009 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
Gregory A EschenauerGregory A Eschenauer
Gregory A Eschenauer
SLSimon W. Lam
Simon W. Lam
PCPeggy L. Carver
Peggy L. Carver